Jun Wu

Jan 10, 2025 | scijournals.onlinelibrary.wiley.com | Jun Wu |Yiheng Wang |Yaxuan Wang |Xiaohong Li

CONFLICTS OF INTEREST The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. Supporting Information Filename Description ps8640-sup-0001-supinfo.docxWord 2007 document , 33.9 MB Data S1. Supporting Information. REFERENCES 1, , , , and , Research tales from the clardy laboratory: function-driven natural product discovery. J Nat Prod 83: 744–755 (2020).

Jan 6, 2025 | onlinelibrary.wiley.com | Jun Yang |Yin Feng Li |Jun Wu |Jun Dai

Conflict of Interest The authors declare no conflict of interest. Supporting Information Filename Description adfm202419681-sup-0001-SuppMat.docx2.4 MB Supporting Information References 1, , , , , , IEEE Antennas Propag. Mag. 2012, 54, 10. 2, , , Science. 2013, 339, 1232009. 3, , , , , , , Science. 2011, 334, 333. 4, , , , , , , , , , Adv. Mater. 2014, 26, 5031. 5, , , , , , , , , , , , Nat. Commun. 2019, 10, 2986. 6, , , , , , , , Phys. Rev. Appl. 2019, 12, 024012.

Nov 27, 2024 | ehp.niehs.nih.gov | Darios Getahun |Jun Wu

Introduction As the perinatal form of major depressive disorder, postpartum depression (PPD) is one of the most frequent childbirth complications.1 Postpartum depressive symptoms affect ∼10%–20% of new mothers worldwide.1–4 Mothers with PPD experience symptoms, such as feelings of anhedonia, worthlessness or guilt, depressed mood, insomnia, or hypersomnia, that can last for up to 1 y postpartum, and infants born to mothers with PPD are at a greater risk of developing behavioral and emotional...

Nov 8, 2024 | mdpi.com | Zilong Wang |Mengya Lu |Jun Wu |Rongsen Liu

All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.

Nov 2, 2024 | nature.com | Jun Wu

AbstractPurpose: Estrogen receptor-positive (ER+), progesterone receptor-negative (PR-) and human epidermal growth factor receptor 2-negative (HER2−) breast cancer (BC) often developed resistance to endocrine treatment (ET). We aimed to explore (1) the different clinicopathological features between ER+/PR+/HER2- and ER+/PR-/HER2- BC, and (2) whether ER+/PR-/HER2- early BC patients could benefit from adjuvant ET.